Postmenopausal Osteoporosis, defined as a bone mineral density (BMD) T-score of ≤ -2.5 at the total hip, femoral neck, or lumbar spine, is a serious problem that predisposes women to increased bone fragility and fracture risk. BMD screening should be considered based on the woman’s risk profile, and is recommended for all women aged ≥ 65years. However, screening rates vary widely, and family physicians may lack a rationale for BMD testing. Thus Postmenopausal Osteopososis often remains undiagnosed until a fracture occurs. The latest, evidence-based guidelines for treating patients with Postmenopausal Osteopososis will be reviewed in this activity.

Welcome to the National Association for Continuing Education webcast from the NACE Emerging Challenges in Primary Care Update: 2012 conference. The topic of this webcast is Emerging Trends in Osteoporosis.

The program was captured live in Denver, Colorado on June 16, 2012 and features Dr. Nelson Watts. Dr. Watts is the Director at Mercy Health Osteoporosis and Bone Health Services in Cincinnati, OH.


Primary care providers


After completing this program, participants should be able to:

— Discuss screening strategies for osteoporosis in postmenopausal women— Identify candidates for pharmacologic treatment of postmenopausal osteoporosis
— Evaluate and compare available therapies for osteoporosis
— Discuss barriers to adherence and effectiveness of osteoporosis therapy


Nelson B. Watts, MD
Director, Mercy Health Osteoporosis and Bone Health Services
Cincinnati, OH


Nelson B. Watts, MD, Speaker, Co-founder, Stockholder and Director of OsteoDynamics. He is a speaker for Amgen, Lily, Novartis and Warner Chilcott. He consults for Amgen, Baxter, Bristol-Myers Squibb, Imagepace, Johnson & Johnson, Lilly Medpace, Merck, Novo Nordisk and Pfizer/Wyeth. He also is a researcher for Amgen, Merck, and NPS.

Vernon Hershberger, MD, FAAFP, Speaker, he does contracted research for Abbott, Amgen, Boehringer Ingelheim, Forest, Pfizer, Purdue, Regeneron and Takeda.

Marjorie M. Luckey, MD, Speaker, is a consultant for Amgen, Novartis, Lilly and Medtronic. She also speaks for Amgen and Novartis.

Harvey C. Parker, Ph.D., Activity Planning Committee, has the following relationship to disclose: co-owner of Specialty Press, Inc. and Health Link Systems, Inc.

Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.

To take this course, go to The log-in information for myCME is the same as McKnight’s. Please note that you will need to complete additional registration information.